Stableford Capital II LLC Cuts Stock Holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Stableford Capital II LLC cut its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 1.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,814 shares of the company’s stock after selling 330 shares during the period. Stableford Capital II LLC owned approximately 0.09% of Establishment Labs worth $1,143,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ESTA. R Squared Ltd purchased a new position in shares of Establishment Labs in the fourth quarter valued at $36,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Establishment Labs in the 3rd quarter worth about $127,000. Black Swift Group LLC purchased a new stake in shares of Establishment Labs during the 3rd quarter valued at about $312,000. Verition Fund Management LLC lifted its holdings in shares of Establishment Labs by 22.8% in the 3rd quarter. Verition Fund Management LLC now owns 9,400 shares of the company’s stock valued at $407,000 after acquiring an additional 1,746 shares during the last quarter. Finally, Maven Securities LTD purchased a new position in Establishment Labs in the third quarter worth about $433,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Price Performance

Shares of ESTA stock opened at $32.05 on Friday. The stock has a 50 day moving average price of $41.64 and a 200 day moving average price of $42.70. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29. Establishment Labs Holdings Inc. has a 52-week low of $30.20 and a 52-week high of $60.12.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Thursday, November 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.02. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The firm had revenue of $40.23 million during the quarter, compared to analyst estimates of $40.60 million. During the same period in the previous year, the firm earned ($1.12) earnings per share. On average, research analysts forecast that Establishment Labs Holdings Inc. will post -2.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. BTIG Research raised their price objective on Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Stephens upgraded shares of Establishment Labs to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Establishment Labs currently has a consensus rating of “Buy” and an average target price of $60.60.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.